A Study to Assess BMS-986460 in Participants With Metastatic Castration-resistant Prostate Cancer (NCT06067841)
A Phase 1, Open-label Study of BMS-986460 in Participants With Metastatic Castration-resistant Prostate Cancer
🩺 Plain-English Summary (8th-Grade Level)
The purpose of this study is to assess the safety, tolerability, and preliminary efficacy of BMS-986460 in men with Metastatic Castration-resistant Prostate Cancer.
Who can join: Review the eligibility criteria below.
Location: Stanford Cancer Center — Palo Alto, California
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (15 Sites)
- Stanford Cancer Center — Palo Alto, California
- Florida Cancer Specialists Sarasota Drug Development Unit — Sarasota, Florida
- Dana-Farber Cancer Institute — Boston, Massachusetts
- Memorial Sloan Kettering Cancer Center — New York, New York
- Duke Cancer Institute — Durham, North Carolina
- Local Institution - 0006 — San Antonio, Texas
- NEXT Oncology — San Antonio, Texas
- Fred Hutchinson Cancer Center — Seattle, Washington
- Local Institution - 0009 — Toronto, Ontario
- Local Institution - 0011 — Montreal, Quebec
- Local Institution - 0018 — Bordeaux, Aquitaine
- Centre Leon Berard — Lyon Cedex08, Auvergne-Rhône-Alpes
- Institut Paoli-Calmettes — Marseille, Nan
- Gustave Roussy — Villejuif, Val-de-Marne
- Local Institution - 0017 — Paris,
📞 Contact the Study Coordinator
Phone: (855) 907-3286
Email: Clinical.Trials@bms.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Metastatic Castration-resistant Prostate Cancer
- A Study of Copanlisib Combined With Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer — San Francisco, California
- Study Evaluating mCRPC Treatment Using PSMA [Lu-177]-PNT2002 Therapy After Second-line Hormonal Treatment — Tucson, Arizona
- ONC-392 Plus Lutetium Lu 177 Vipivotide Tetraxetan in Patients With mCRPC — Sacramento, California
- FPI-2265 (225Ac-PSMA-I&T) for Patients With PSMA-Positive Metastatic Castration-Resistant Prostate Cancer (mCRPC) — Duarte, California
- A Study to Assess Adverse Events, and How Intravenously (IV) Infused ABBV-969 Moves Through the Bodies of Adult Participants With Metastatic Castration-Resistant Prostate Cancer — Duarte, California
- FOR46 in Combination With Enzalutamide in Patients With Metastatic Castration Resistant Prostate Cancer — San Francisco, California
Explore by condition: All Metastatic Castration-resistant Prostate Cancer clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.